在转移性割敏感前列腺癌中,Apalutamide与Enzalutamide的整体存活率相比
Mehmet A Bilen1, Benjamin Lowentritt2, Ibrahim Khilfeh3
1Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Advances in therapy
|May 29, 2025
概括
在转移性割敏感前列腺癌患者中,阿帕胺与恩扎胺相比,在24个月后改善了生存结果. 这项研究为mCSPC治疗的雄激素受体通路抑制剂提供了宝贵的见解.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在转移性割敏感前列腺癌 (mCSPC) 中,不同类型的雄激素受体通路抑制剂 (ARPI) 的生存结果的直接比较缺乏.
- 了解ARPI的比较有效性对于优化mCSPC治疗策略至关重要.
研究的目的:
- 为了比较24个月的整体存活期 (OS) 在mCSPC的ARPI-naïve患者中,阿帕胺和酶胺之间.
- 为两种常规处方的ARPI提供生存结果的对比分析.
主要方法:
- 使用治疗权重的逆概率 (IPTW) 对非识别的美国临床和保险索赔数据 (2019年12月 - 2023年12月) 的回顾性,因果纵向分析.
- 包括从未使用过ARPI的mCSPC患者,开始使用apalutamide或enzalutamide.
- 权重考克斯比例危险模型被用于24个月后的OS初级和探索性分析以及整体随访.
主要成果:
- 该研究包括1810名开始服用阿帕胺的患者和1909名开始服用恩扎胺的患者,在IPTW后的基线特征均衡.
- 在开始服用阿帕胺与恩扎胺 (HR 0.77; 95% CI 0.62, 0.96; p=0.019) 的患者中,观察到24个月死亡风险的统计学显著降低23%.
- 当使用所有可用的随访数据 (HR 0.77;95% CI 0.64,0.93;名义p=0.008) 时,这些发现保持一致.
结论:
- 与ARPI-naïve患者的mCSPC相比,阿帕胺治疗导致24个月生存结果优于恩扎胺.
- 这种因果分析强调阿帕胺是提高这种患者群体生存率的潜在更有效选择.
- 进一步的长期后续研究是有必要的,以充分阐明这些药物的比较治疗影响.
相关概念视频
01:21Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
01:20Actuarial Approach
140
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
140
01:20Comparing the Survival Analysis of Two or More Groups
303
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
303
01:24Kaplan-Meier Approach
281
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
281